E Fund Management Co. Ltd. Has $457,000 Position in Insmed Incorporated (NASDAQ:INSM)

E Fund Management Co. Ltd. lessened its position in Insmed Incorporated (NASDAQ:INSM) by 56.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,815 shares of the biopharmaceutical company’s stock after selling 8,762 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Insmed were worth $457,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of INSM. Nisa Investment Advisors LLC grew its holdings in shares of Insmed by 8.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 135 shares in the last quarter. CWM LLC grew its stake in Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 155 shares in the last quarter. First Horizon Advisors Inc. increased its position in shares of Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 287 shares during the last quarter. Beacon Financial Advisory LLC raised its stake in shares of Insmed by 4.6% during the 2nd quarter. Beacon Financial Advisory LLC now owns 13,825 shares of the biopharmaceutical company’s stock worth $926,000 after purchasing an additional 605 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its holdings in shares of Insmed by 1.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 38,232 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 610 shares during the last quarter.

Analysts Set New Price Targets

INSM has been the topic of several analyst reports. Stifel Nicolaus upped their price target on shares of Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Barclays raised their target price on shares of Insmed from $40.00 to $63.00 and gave the company an “overweight” rating in a research note on Wednesday, May 29th. UBS Group boosted their price target on Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Evercore ISI raised their price objective on Insmed from $42.00 to $75.00 and gave the company an “outperform” rating in a research report on Friday, June 21st. Finally, Guggenheim lifted their target price on Insmed from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.19.

Insmed Trading Down 0.5 %

INSM stock opened at $72.87 on Thursday. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53. The company has a market capitalization of $10.83 billion, a PE ratio of -13.93 and a beta of 1.11. The company’s 50-day simple moving average is $74.77 and its 200 day simple moving average is $51.39. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The business had revenue of $90.34 million for the quarter, compared to analysts’ expectations of $87.95 million. During the same period in the prior year, the company earned ($1.78) earnings per share. The firm’s revenue for the quarter was up 17.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Insmed Incorporated will post -5.42 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Michael Alexander Smith sold 27,871 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares in the company, valued at approximately $5,045,093.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the transaction, the insider now directly owns 67,856 shares in the company, valued at approximately $5,045,093.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. The disclosure for this sale can be found here. Insiders have sold a total of 78,882 shares of company stock worth $5,765,446 in the last 90 days. Company insiders own 4.60% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.